Skip to main content
TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · IEX Real-Time Price · USD
5.73
-0.20 (-3.37%)
At close: Jul 2, 2024, 4:00 PM
5.45
-0.28 (-4.89%)
After-hours: Jul 2, 2024, 4:12 PM EDT

TScan Therapeutics Revenue

TScan Therapeutics had revenue of $14.81M in the twelve months ending March 31, 2024, down -14.47% year-over-year. Revenue in the quarter ending March 31, 2024 was $566.00K, a -91.68% decrease year-over-year. In the year 2023, TScan Therapeutics had annual revenue of $21.05M with 55.52% growth.

Revenue (ttm)
$14.81M
Revenue Growth
-14.47%
P/S Ratio
20.45
Revenue / Employee
$92,000
Employees
161
Market Cap
302.90M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202321.05M7.51M55.52%
Dec 31, 202213.54M3.39M33.47%
Dec 31, 202110.14M9.06M834.65%
Dec 31, 20201.09M--
Dec 31, 20190--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
DocGo 703.37M
Nevro 430.75M
OraSure Technologies 304.64M
Zynex 188.68M
Spok Holdings 140.75M
ADC Therapeutics 68.62M
SOPHiA GENETICS 64.18M
Verrica Pharmaceuticals 8.91M
Revenue Rankings

TCRX News

More News